申请人:Hoffmann-La Roche Inc.
公开号:US05238962A1
公开(公告)日:1993-08-24
Benzamides of the formula ##STR1## wherein R.sup.1 and R.sup.2 each independently is hydrogen, halogen, lower alkyl, lower alkoxy, cyano, trifluoromethyl, sulfamoyl, mono(lower alkyl)sulfamoyl or di(lower alkyl)sulfamoyl or R.sup.1 and R.sup.2 on adjacent carbon atoms together are a methylenedioxy group, with the proviso that R.sup.2 is different from hydrogen when R.sup.1 are bromine in the 3-position, and their pharmaceutically acceptable acid addition salts have monoamine oxidase inhibiting properties with low toxicity and can accordingly be used for the treatment of depressive states and Parkinsonism.
苯甲酰胺的化学式为##STR1##其中R.sup.1和R.sup.2分别独立地为氢、卤素、低碳烷基、低碳氧基、氰基、三氟甲基、磺酰胺基、单(低碳烷基)磺酰胺基或二(低碳烷基)磺酰胺基,或者R.sup.1和R.sup.2在相邻碳原子上共同形成亚甲二氧基基团,但R.sup.1为溴在3位时,R.sup.2与氢不同,它们的药用可接受的酸盐具有低毒性的单胺氧化酶抑制作用,因此可用于治疗抑郁症和帕金森病。